| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Published online 13 December 2004
British Medical Bulletin, Vol. 71 © The British Council 2004; all rights reserved
Current status of bacterial translocation as a cause of surgical sepsis
Combined Gastroenterology Unit, Scarborough Hospital, Scarborough, UK
Correspondence to: John MacFie, The Combined Gastroenterology Unit, Scarborough Hospital, Woodland Drive, Scarborough, North Yorkshire YO12 6QL, UK. E-mail: Johnmacfie@aol.com
| The first 150 words of the full text of this article appear below. |
| Background |
|---|
In recent years it has been increasingly recognized that the gastrointestinal tract has functions other than simply the digestion and excretion of foodstuffs. The gut is also a metabolic and immunological organ that serves as a barrier against living organisms and antigens within its lumen. This role is termed gut barrier function. The fact that luminal contents in the caecum have a bacterial concentration of the order of 1012 organisms per millilitre of faeces,1 whilst portal blood and mesenteric lymph nodes are usually sterile, dramatically illustrates the efficacy of this barrier function.
The idea that the alimentary tract, teeming with its own bacterial flora, could represent a source of sepsis under certain conditions has interested clinicians for many years. This theory, usually referred to as the gut origin of sepsis hypothesis, is not new. In the late nineteenth century, the idea developed that peritonitis could result from the passage of
| Bacterial translocation: human studies |
|---|
| Factors influencing the prevalence of bacterial translocation |
|---|
Host defence: the mucosal barrier and permeabilityGastrointestinal microfloraImmune statusMiscellaneous factors
| Bacterial translocation and nutritional support |
|---|
| Gut-specific nutrients |
|---|
| Bacterial translocation, sepsis and multiple organ failure |
|---|
| Conclusion |
|---|
This article has been cited by other articles:
![]() |
C. Alberda, L. Gramlich, J. Meddings, C. Field, L. McCargar, D. Kutsogiannis, R. Fedorak, and K. Madsen Effects of probiotic therapy in critically ill patients: a randomized, double-blind, placebo-controlled trial Am. J. Clinical Nutrition, March 1, 2007; 85(3): 816 - 823. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Kotanko, M. Carter, and N. W. Levin Intestinal bacterial microflora--a potential source of chronic inflammation in patients with chronic kidney disease Nephrol. Dial. Transplant., August 1, 2006; 21(8): 2057 - 2060. [Full Text] [PDF] |
||||

